DexCom, Inc. Stock News
$70.43
2.07%
yesterday
Nasdaq,
Sep 20, 10:14 pm CET
DexCom, Inc. Stock News
Neutral
PRNewsWire
●
about 9 hours ago
NEW YORK , Sept. 20, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the "Class Period"), of the important October 21, 2024 lead plaintiff deadline.
Neutral
PRNewsWire
●
about 9 hours ago
LOS ANGELES , Sept. 20, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM).
Neutral
GlobeNewsWire
●
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options
Neutral
Business Wire
●
3 days ago
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's groundbreaking NIL (name, image, likeness) program exclusively for college athletes with diabetes. Heralded by Ad Age as a Top 5 NIL Partnership after its inaugural season i...
Neutral
PRNewsWire
●
3 days ago
LOS ANGELES , Sept. 17, 2024 /PRNewswire/ -- The Law Offices of Frank R.
Neutral
PRNewsWire
●
7 days ago
NEW YORK , Sept. 14, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the "Class Period"), of the important October 21, 2024 lead plaintiff deadline.
Positive
The Motley Fool
●
7 days ago
Novo Nordisk is the leader in developing drugs in a fast-growing area. DexCom's recent drop doesn't take away from its long runway for growth.
Neutral
PRNewsWire
●
9 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
